GlassScriptPhysician profile
Brittany C Starnes
NPI 1588014310
$12,279.07
in general payments reported to CMS, 2019-2025
27 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $342 · 2022: $813 · 2023: $3,104 · 2024: $5,770 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,935.04 |
| Education | $189.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,602.74 | 2022-2025 | |
| Genzyme Corporation | $1,365.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,095.84 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $1,035.13 | 2022-2025 | Ilumya |
| Janssen Biotech, INC. | $801.24 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $800.34 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $718.80 | 2023-2024 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $716.54 | 2024-2025 | Clindacin Etz, Neo-Synalar, Neuac |
| Arcutis Biotherapeutics, INC. | $548.72 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $519.47 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $371.88 | 2023-2025 | |
| Galderma Laboratories, L.P. | $307.90 | 2022-2024 | Aklief, Epsolay, Oracea |
| Pfizer INC. | $296.51 | 2022-2025 | |
| Hill Dermaceuticals, INC. | $187.44 | 2022-2024 | Tolak |
| Incyte Corporation | $173.28 | 2024 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $133.44 | 2023-2025 | |
| Amgen INC. | $128.15 | 2022-2024 | Otezla |
| Ucb, INC. | $113.10 | 2022-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.58 | 2023-2025 | Cabtreo, Jublia |
| Almirall LLC | $98.10 | 2023-2024 | Klisyri, Seysara |
| Leo Pharma INC. | $32.02 | 2023-2024 | Adbry |
| Organon LLC | $30.03 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $21.57 | 2023 | |
| Gilead Sciences, INC. | $21.55 | 2021 | |
| Lnhc, INC | $18.67 | 2025 | Zelsuvmi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.65 | 2022 | |
| Botanix Sb INC | $17.15 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Starnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.